60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
09 juil. 2024 06h31 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
27 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
11 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
30 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
20 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS symptoms.
60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
15 mai 2024 13h45 HE
|
Sixty Degrees Pharmaceuticals
SXTP posts Q1 2024 net product revenues increase of 515% year-over-year to $105.7 thousand in a Q1 earnings report released today.
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
08 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma plans clinical trial of Tafenoquine for Babesiosis. Letter to Journal of Infectious Diseases outlines protocol. Enrollment starts summer.
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
02 mai 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
SXTP received FDA comments on tafenoquine-babesiosis trial protocol; no major changes are needed. Trial planning and execution to proceed as planned.
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
03 avr. 2024 07h58 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease.
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
08 févr. 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
Kristen Landon appointed Chief Commercial Officer at 60 Degrees Pharma leading ARAKODA® relaunch for malaria prevention and expanded tick-borne strategy.